Cost-effectiveness analyses and modelling the lifetime costs and benefits of health-behaviour interventions

Chronic Illness

Volumn 2, Issue 2, 2006, Pages 97-107

  Graves, Nicholas ^a   McKinnon, Loretta ^a   Reeves, Marina ^b   Scuffham, Paul ^c   Gordon, Louisa ^b   Eakin, Elizabeth ^d  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b VIERTEL CENTRE FOR RESEARCH IN CANCER CONTROL   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cost effectiveness; Health behaviour; Markov chain; Patient compliance; Quality adjusted life years

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA COLLECTION METHOD; DIABETIC DIET; ECONOMIC EVALUATION; HEALTH BEHAVIOR; HEALTH STATUS; HUMAN; INTERVENTION STUDY; LIFESPAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SIMULATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HEALTH BEHAVIOR; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; LIFE STYLE; MALE; MARKOV CHAINS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; QUEENSLAND; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33745751713     PISSN: 17423953     EISSN: 17459206     Source Type: Journal    
DOI: 10.1179/174592006X110978     Document Type: Article

References (20)

1. Murray CJL, Lopez AD. Quantifying the burden of disease and injury attributable to ten major risk factors. In: Murray CJL, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mor tality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996, 295-325.
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States. JAMA 2000; 291: 1238-45.
3. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd edn. Oxford: Oxford University Press, 1997.
4. Gold MR, Siegel JE, Russell LN, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
5. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics 1997; 6: 217-27.
6. Briggs A, Schulpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.
7. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38.
8. Clemen RT. Making hard decisions. An introduction to decision analysis. Pacific Grove: Duxbury Press, 1996.
9. Banks J, Carson JS, Nelson BL. Discrete event simulation. Englewood Cliffs: Prentice-Hall, 1996.
10. Stephenson J, Bauman A, Armstrong T, Smith B, Bellew B. The costs of illness attributable to physical inactivity in Australia. A preliminary study. Canberra: Department of Health and Ageing, Australia, 2000.
11. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1115-28.
12. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Economics 2002; 21: 271-92.
13. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3: 1-176.
14. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-83.
15. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 381-3.
16. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counselling. JAMA 1996; 275: 1247-52.
17. Secker-Walker RH, Worden JK, Holland RR, Flynn BS, Detsky AS. A mass media programme to prevent smoking among adolescents: costs and cost effectiveness. Tob Control 1997; 6: 207-12.
18. de Vries SO, Visser K, de Vries JA. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology 2002; 222: 25-36.
19. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil 2000; 20: 147-55.
20. Segal L, Dalton A, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. J Health Promotion Int 1998; 13: 197-210.